General cardiovascular risk profile for use in primary care: the Framingham Heart Study.
Ralph B D'Agostino, Ramachandran S Vasan, Michael J Pencina...
https://pubmed.ncbi.nlm.nih.gov/18212285Actively Recruiting
Age: 18Years - 80Years
MALE
ID06163924
Effect of Multidisciplinary Care on Cardiovascular Risk in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Led by Chinese University of Hong Kong · Updated on 2025-05-06
130
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prostate cancer is a common and often slow-progressing cancer in adult men, with many patients living several years even with metastatic disease. Androgen deprivation therapy (ADT) is widely used to control prostate cancer, but it may increase the risk of cardiovascular problems. Researchers are evaluating whether a multidisciplinary care approach with close cardiovascular monitoring can reduce these risks and improve health outcomes for prostate cancer patients receiving ADT. This observational study aims to fill gaps in knowledge about the best ways to monitor and manage cardiovascular risks in these patients.
CONDITIONS
Brief Title
The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
Who Can Participate
Age: 18Years - 80Years
MALE
Eligibility Criteria
You may qualify if you...
- Adult men aged 18 to 80 years
- Histologically or clinically diagnosed prostate cancer
- Planned to receive androgen deprivation therapy for at least 1 year
You will not qualify if you...
- History of major atherosclerotic cardiovascular disease, including recent acute coronary syndrome within 12 months, prior myocardial infarction (other than recent acute coronary syndrome), ischemic stroke, or symptomatic peripheral arterial disease
- Received neoadjuvant or adjuvant hormone therapy within 1 year before study
- Unable or unwilling to provide written informed consent
- Participating in another investigational program with non-routine interventions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - 1 year
Participants who are receiving androgen deprivation therapy are observed to assess cardiovascular risk factors and changes over time.
Regular visits during the year to assess cardiovascular health and risk factors
Trial Site Locations
Total: 1 location
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Loading map...
Research Team
C
Chi Fai NG, Professor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG).
Mercedeh Ghadessi, Rui Tang, Joey Zhou...
https://pubmed.ncbi.nlm.nih.gov/32164754Letter by Ng et al Regarding Article, "Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial".
Chi Fai Ng, Jeremy Y C Teoh, Peter K F Chiu
https://pubmed.ncbi.nlm.nih.gov/35312383Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Renato D Lopes, Celestia S Higano, Susan F Slovin...
https://pubmed.ncbi.nlm.nih.gov/34459214How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk: A Therapeutic Tightrope.
Vivek Narayan, Ashley E Ross, Ravi B Parikh...
https://pubmed.ncbi.nlm.nih.gov/34988484The European Society of Cardiology Cardio-Oncology Guidelines: Evidence Base, Actionability, and Relevance to Clinical Practice.
Darryl P Leong, Som D Mukherjee
https://pubmed.ncbi.nlm.nih.gov/368759152022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R Lyon, Teresa López-Fernández, Liam S Couch...
https://pubmed.ncbi.nlm.nih.gov/36017568A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.
Joseph K M Li, Lynn L Wang, Christine Y P Wong...
https://pubmed.ncbi.nlm.nih.gov/33850270Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms.
Jeremy Yuen-Chun Teoh, Xiao-Yu Tian, Christine Yim-Ping Wong...
https://pubmed.ncbi.nlm.nih.gov/34570375Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study.
Chris Wong, Peggy Chu, Jeremy Teoh...
https://pubmed.ncbi.nlm.nih.gov/35217907